Investing.com - Financial Markets Worldwide
Get 40% Off
Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious OutperformanceFind Stocks Now

Pharming Group NV (PHAR)

Amsterdam
Symbol
Exchange
Currency
PHARAmsterdamEUR
PHARMaBATS EuropeEUR
PHARNASDAQUSD
PHGNFrankfurtEUR
Currency in EUR
Disclaimer
0.912
+0.012(+1.28%)
Real-time Data

PHAR Comments

Shes taking off today
Sell
they go quick road on leniolisib and u wanna sell? 🤣
Consolideerd een beetje op het moment.
0.85
Prepare for very good news, coming before the end off Q3.cheers to Pharming
Oh dear....not the best Q2 results, but expected. Diluted EPS hasn't changed. Outlook is OK I think.
financial results tomorrow 💪
I’m sorry to say but this Dutch company is probably the worst stock in Holland, where it fell from 227 € to only twenty cents.
America is waking up! Pharming is the best Healtcare / Biothechnology stock to buy in 2021! The future of this company is very good. It's up to you! Cheers to day!
Here we go
patent pending in the US. NICE 1
what happen to their COVID vaccine?
never had a vaccin. ruconest cured people after theyhad complications due to covid
A dead bird. Waiting 4 martch before closing the door for ever.
hahaha
ipo boring stock
Today at 9:00 am NL time , pharming buy buy buy ...... At the AEX index
Maybe a other day
tomorrow when it is red
part 3 Thesis 10: Did Pharming have butter on its head not to publish this Thesis 11: Is the AFM not expert enough to enforce the rules of the game, since the necessary expertise is required to make sense of the trial data. Thesis 12: Would it not help to give the AFM a hand on the way, by providing insight into what might be the purport of the trial in the context of the AFM's duty to report on press releases. Salut
part 2 Thesis 4: The company that this FDA approval is given to is the company that directly owns or licenses this drug. In this case, it is Pharming. Theorem 5: So this would mean, that Imu.... would only be allowed to start a phase 4 study with Ruconest after Pharming has received FDA approval to use Ruconest for phase 3 post Covid. Statement 6: There is no question of a period of silence from Pharming. Has also been discussed several times etc. And also confirmed by investor relations of Pharming. Because Nasdaq listing is not an IPO, but a simple listing where no additional shares have been issued. Statement 7: The market for post Covid is probably a multiple of HAE, given that the USA has over 10 mio Covid infections. Thesis 8: The only commercial product (combo product + drug) Pharming has is Ruconest against HAE. . Thesis 9: With that comes a very large application opportunity.
I found this and translated to English. part 1 The passenger wrote on 17 January 2021 20:02: Hi, I am trying to make 1 more attempt to clarify my position. Just a few statements / facts in a row according to yours truly, a layman in this field, but eager to learn, and have already read quite a bit, to give an insight into my limited, not omniscient perception. Thesis 1: It should not matter who leads or initiates this research. Any commercial company with certain licenses may initiate research, provided permission is obtained. Thesis 2: In order to get approval to start a trial of a drug in phase 4,, however, approval must first have been granted to use this drug in phase 3. Thesis 3: The drug in question is Ruconest. There are several trials running here. I have not yet seen any approval from the FDA to use Ruconest for phase 3 against post Covid. Translated with www.DeepL.com/Translator (free version)
What's happening?
Any covid news?
it is DEAD and BURIED
Still waiting Americans wake up and buy this opportunity at ML term ;-)
Spot onA bargain
Golden cross incoming!
:atest on the IPO approval - https://sec.report/Document/0001354457-20-000824/ as Certification by an exchange approving securities for listing. Fingers crossed on the IPO tomorrow :)
looks like the US IPO is moved to tomorrow according to SEC - https://sec.report/Document/0001193125-20-324278/
https://seekingalpha.com/article/4395655-pharming-group-lines-up-u-s-offering-plan - "As to valuation, the firm’s enterprise value will likely exceed $1 billion after a successful offering".
https://www.biopharmcatalyst.com/calendars/ipo-calendar  - December 2020 Biotech IPOs are all up from 26% to 251% as of December 20th. Let's see what's in store for Pharming 🤞
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.